Around the globe, infectious diseases pose a significant threat, leading to increased morbidity and mortality. We, at our prestigious institution, do not relent in our efforts to advance the development of therapeutics in the field of infectious diseases. Ensuring that all these aforementioned goals are met, we offer a broad scope of preclinical research services to tackle the impenetrable puzzles these diseases impose.
Introduction to Infectious Disease Therapeutic Development
Infectious diseases can be defined as range of disorders that are caused by the invasions by pathogenic microorganisms that disturb the normal physiological functioning of a person's body. Such microorganism can be in the form of bacteria, viruses, fungi or parasites which can cause mild or severe disorders.
Infectious disease therapeutic development involves the stages of constructing, formulating, and evaluating therapies for prevention and therapeutics of infectious diseases. It includes target selection, drug development, preclinical and clinical testing, and obtaining marketing authorization. One of the greatest health challenges is to develop effective treatments that will control the infectious agent, reduce symptoms, lessen contagion, and improve prognosis.
Fig.1 The global burden of infectious diseases demonstrates the high priority of research into infectious disease drugs. (Kirtane A. R., et al., 2021)
Types of Infectious Disease Therapies
The therapeutic approaches for infectious diseases are diverse in scope with each strategy aimed at combatting specific infectious agents. The following are the main categories of infectious disease therapy:
- Antiviral therapies are directed towards virulent infections occurring in cases like HIV, influenza, hepatitis, herpes, or COVID - 19.
- Antibacterial therapies are deployed to fight bacterial infections through the destruction of certain bacterial structures or their metabolic pathways.
- Antifungal therapies focus on specific physiological mechanisms and structures of fungi to suppress their growth and reproduction.
- Antiparasitic therapy is the branch of medicine that seeks to destroy or control parasites living within a host.
- Immunotherapies, including monoclonal antibodies and therapeutic vaccines can be useful for viral, bacterial, fungal, and parasitic infections.
Table 1 Developmental pipeline of therapies for infectious diseases. (Zumla A., et al., 2016)
| Types of Therapy |
Examples of Therapy |
Developmental Stage |
| Repurposed drug |
Imatinib, verapamil, metformin, ibuprofen |
Preclinical/clinical (early phase) |
| Cytokine therapy |
Interleukin 2, GM-CSF, interferon γ, interleukin 12 (early stage) |
Clinical (late phase) |
| Monoclonal antibody |
Anti-TNFα, anti-interleukin 6, anti-VEGF |
Preclinical/clinical (early phase) |
| Vitamin |
Vitamin D3 |
Clinical (late phase) |
| Cellular therapy |
Autologous mesenchymal stromal cells, T cells |
Clinical (early phase) |
| Repurposed drug |
Valproic acid, vorinostat |
Clinical (early phase) |
| Monoclonal antibody |
Anti-PD-1 |
Preclinical |
| Cellular therapy |
CD19 CAR (for Epstein-Barr virus [EBV] B-cell lymphoma), in-vitro-expanded EBV-specific CD8 CTLs |
Depletion of viral reservoirs to deter progression to lymphoma |
| Cytokine therapy |
Pegylated interferon α and β |
In clinical use |
| Repurposed drug |
Imiquimod, resiquimod |
In clinical use |
| Cytokine therapy |
Interleukin 2, interferon γ (early stage) |
Not yet tested in schistosomiasis |
| Cellular therapy |
MSCs (late stage) |
Not yet tested in trypanosomiasis |
| Recombinant protein |
Peroxiredoxin (as adjuvant to vaccine candidate) |
Preclinical |
Our Services
Creating efficient therapeutics for infectious diseases is incredibly critical. Our company is dedicated to making a difference in the field of infectious disease therapeutics by offering comprehensive services. Our focus lies in the areas of drug discovery, preclinical testing, and development of disease models. We aim to professionally offer customized therapy development solutions to pharmaceutical companies around the world.
Our reputable firm, with regard to our vast experience, brings forward a variety of therapy development services from different angles to serve clientele better. Because our resources are abundant, we are able to deal with different aspects of therapy development at a wide range scope ensuring integrated and tailor fitted answers to your problems.
By Types of Pathogen
By Types of Therapy
The realm of therapeutic development is an ever-evolving landscape, with emerging technologies presenting exciting opportunities for innovation and advancement. At our esteemed organization, we wholeheartedly embrace these cutting-edge advancements to enhance the efficacy and accessibility of therapeutics. If our comprehensive suite of services has piqued your interest, we earnestly encourage you to reach out to us without any reservations.
References
- Kirtane Ameya R., et al. "Nanotechnology approaches for global infectious diseases." Nature Nanotechnology 16.4 (2021): 369-384.
- Zumla Alimuddin, et al. "Host-directed therapies for infectious diseases: current status, recent progress, and future prospects." The Lancet Infectious Diseases 16.4 (2016): e47-e63.
All of our services and products are intended for preclinical research use
only and cannot be used to diagnose, treat or manage patients.
